DS-6930

• Description :

  DS-6930 is a potent and selective agonist of PPARγ, with an EC50 of 41 nM. DS-6930 could robust reduce plasma glucose (PG), and with fewer PPARγ-related adverse effects than Rosiglitazone. DS-6930 can be used for the research of diabetes[1].

• UNSPSC :

  12352005

• Target :

  PPAR

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/ds-6930.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(O)C1=CC=CC(OCC2=NC3=CC=C(OC4=NC=C(C)C=C4C)C=C3N2C)=C1

• Molecular Formula :

  C23H21N3O4

• Molecular Weight :

  403.43

• References & Citations :

  [1]Shinozuka T, et, al. Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization. Bioorg Med Chem. 2018 Oct 1;26 (18) :5099-5117.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  PPARγ

• CAS Number :

  [1242328-82-0]